South Korea has published its latest official healthcare workforce survey, providing a new government benchmark for physician remuneration and working conditions across the country's healthcare system.

The FDA has approved the first surgically implanted heart valve designed to be enlarged as a child grows, potentially reducing the need for repeat operations.

SpyGlass Pharma has acquired Advanced Vision Science for approximately $13 million, bringing manufacturing of a key intraocular lens used in its drug-delivery platform in-house.

Novotech has agreed to acquire Agilex Biolabs, adding specialist bioanalytical laboratory capabilities to its Australian clinical-development platform.

Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates.

Sanofi and Regeneron have expanded their long-running immunology alliance with four next-generation antibody programmes in a deal worth up to $8 billion.

Average annual salaries across China's health and social work sector increased in 2025, with employees in urban non-private organisations earning almost twice the average recorded in private organisations, according to new official data.

New 2026 compensation data provides a snapshot of physician salaries across medical specialties in Brazil, highlighting significant differences in formal employment pay and the importance of looking beyond base salary when assessing doctors’ total earnings.

ALK is investing approximately DKK 500 million to expand its long-term manufacturing partnership with Catalent and increase capacity for fast-dissolving allergy immunotherapy tablets.

The FDA has expanded Camzyos approval to paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy who weigh at least 30kg.

The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.

Medscape's 2026 Canada physician compensation report shows average total physician compensation of C$394,000, while fewer than half of respondents say they feel fairly paid.

Novo Nordisk has secured rights outside Greater China to Hengrui Pharma's once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 in a deal worth up to $2.6bn.

AstraZeneca is investing $2bn in Summit Therapeutics alongside a clinical collaboration focused on combinations involving the PD-1/VEGF bispecific antibody ivonescimab.

The Council has formally adopted its position on the EU pharmaceutical package, moving the bloc's largest overhaul of medicines legislation in decades toward its final legislative stages.

STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.

The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder.

Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.

The FDA has approved Teva's DEGEVMA as a biosimilar to Xgeva across all reference-product indications, expanding competition in denosumab treatment.

The approval introduces a selective dopamine D1/D5 receptor partial agonist as a new oral treatment option for adults with Parkinson's disease.